Cohance Lifesciences Expands ADC Push Amid Stock Weakness

Cohance Lifesciences plans $18 million in ADC-focused investments, while the stock remains nearly 66% below its December 2024 peak. Cohance Lifesciences Ltd. (NSE:

) is strengthening its presence in the rapidly growing antibody-drug conjugate (ADC) segment through two proposed strategic investments worth $18 million. The company plans to invest an additional $13 million in NJ Bio and deploy $5 million to acquire a controlling stake in Aruka Bio. Both transactions are expected to be funded through internal accruals and are aimed at enhancing Cohance's capabilities across ADC research, development and manufacturing. Despite the strategic expansion (proposed), investor sentiment remained cautious. Cohance Lifesciences shares closed at ₹456.60 on September 4, 2026, down 0.92% for the session. The stock has largely traded in a broad range over the past four months following a sharp correction from its historic highs. From its all-time high of ₹1,360, recorded in December 2024, the stock is trading down by approximately 66%. It also touched a 52-week low of ₹267.85 in March 2026 (the stock has declined over 80% from its all time high). The proposed investments underscore the company's long-term focus on expanding its presence in high-growth pharmaceutical segments. However, investors are likely to remain focused on execution, revenue contribution from these investments and the company's ability to translate strategic initiatives into sustainable growth and profitability. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.